Paradigm Capital Management Inc. NY Acquires 513,200 Shares of Enovis Co. (NYSE:ENOV)

Paradigm Capital Management Inc. NY lifted its stake in Enovis Co. (NYSE:ENOV - Free Report) by 2,566.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 533,200 shares of the company's stock after buying an additional 513,200 shares during the period. Enovis makes up approximately 1.1% of Paradigm Capital Management Inc. NY's investment portfolio, making the stock its 27th biggest position. Paradigm Capital Management Inc. NY owned about 0.94% of Enovis worth $23,397,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. UMB Bank n.a. raised its position in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after buying an additional 437 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Enovis by 19.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after purchasing an additional 2,518 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Enovis during the fourth quarter worth $437,000. Tributary Capital Management LLC lifted its stake in Enovis by 33.9% during the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock worth $24,840,000 after purchasing an additional 143,258 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in shares of Enovis by 12.5% in the 4th quarter. Park Avenue Securities LLC now owns 11,988 shares of the company's stock valued at $526,000 after purchasing an additional 1,333 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ENOV. JMP Securities lowered their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group dropped their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC decreased their target price on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Enovis has a consensus rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Stock Performance

Enovis stock opened at $35.45 on Tuesday. The business has a 50 day moving average of $35.13 and a 200-day moving average of $41.37. The company has a market capitalization of $2.03 billion, a P/E ratio of -16.19 and a beta of 1.79. Enovis Co. has a 1 year low of $29.32 and a 1 year high of $52.76. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. The firm had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company's revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.50 EPS. On average, equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.